Windtree Therapeutics Inc. (WINT) shares were up 43.09 percent at $2.59 in pre-market trading. The closing price of WINT stock in the last session was $1.81, a decline of 10.40% or $0.21. A daylong fluctuation between $1.81 and $1.95 marked the company’s shares. The number of shares of WINT stock traded on the day was 0.51 million, lower than the company’s 50-day daily volume of 3.5 million and lower than its Year to Date volume of 1.48 million. WINT stock is surging and is likely to be recouping the loss it incurred last session.

How is WINT Stock doing lately?

To help patients in times of crisis, Windtree Therapeutics is developing a number of late-stage interventions to treat acute cardiovascular disorders and pulmonary disorders. In an attempt to take advantage of the latest clinical advances, WINT is developing a multi-asset franchise around compounds that can activate SERCA2a, with the lead candidate istraroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock.

In addition, WINT is currently developing AEROSURF for treating premature infants with respiratory distress syndrome, and working with its licensee in Asia, Lee’s HK, to facilitate clinical development of the surfactant in treating lung injury caused by chemical and radiation insults. WINT’s portfolio includes rostafuroxin, a novel precision drug that targets hypertensive patients with certain genetic profiles.

As part of its quarterly financial report last Thursday, Windtree Therapeutics provided key business updates and provided its second-quarter results.

Q2 2021 Financial Results:

• WINT reported a $45.4 million operating loss for the second quarter ended June 30, 2021, including an impairment charge of $37.8 million on our rostafuroxin intangible asset, compared to a $7.9 million operating loss in the second quarter of 2020.
• For the second quarter of 2021, WINT spent $4.2 million on research and development, down from $4.5 million for the second quarter of 2020.
• A total of $3.4 million was spent by WINT on general and administrative operations during the second quarter of 2021, compared to $3.5 million during the second quarter of 2020.
• WINT also reported a net loss of $37.4 million ($1.42 per common share) for the third quarter ending June 30, 2021, compared with a net loss of $9.6 million ($0.63 per basic share) for the third quarter ending June 30, 2020.

A key update on business operations:

Windtree Therapeutics (WINT) has been advancing multiple business development activities, including exploring licensing in Asia with istaroxime to fund clinical development costs and activities for chronic heart failure, and with the SERCA2a activators around the world. After engaging with potential licensees, WINT determined that additional small clinical studies would be necessary to gain out-licensing rights for rostafuroxin.